Stock Events

Stock Events

Rigel Pharmaceuticals 

$43.62
88
+$1.17+2.76% Tuesday 20:00
-$1.47-3.37%Tuesday 23:34After hours

Statistics

Day High
43.63
Day Low
43.6
52W High
52.24
52W Low
24.95
Volume
7,753
Avg. Volume
-
Mkt Cap
814.82M
P/E Ratio
2.21
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.09
1.15
2.22
3.28
Expected EPS
0.920828
Actual EPS
N/A

Financials

124.72%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
294.28MRevenue
367.02MNet Income

Analyst Ratings

71.67Average Price Target
The highest estimate is 85.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RIGL. It's not an investment recommendation.
Amazon
22
AMZN
Tesla
20
TSLA
Microsoft
19
MSFT
NVIDIA
18
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences competes in the biopharmaceutical sector focusing on antiviral drugs, directly competing with Rigel's focus on novel small-molecule drugs for hematologic disorders, cancer, and rare immune diseases.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech firm with a broad portfolio including treatments for cancer and inflammatory diseases, overlapping with Rigel's therapeutic areas.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation specializes in oncology and inflammation, directly competing with Rigel's research and development in cancer and rare blood disorders.
Novartis
NVS
Mkt Cap286.78B
Novartis AG, with its extensive research in oncology and autoimmune diseases, competes in the same therapeutic areas as Rigel Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb operates in the oncology, hematology, immunology, and cardiovascular sectors, overlapping with Rigel's focus areas.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the biopharmaceutical field with a focus on immunology and oncology, directly competing with Rigel's product offerings.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a diverse portfolio including oncology and inflammation treatments, making it a competitor in Rigel's market space.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, competes across a broad range of therapeutic areas including those targeted by Rigel.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals focuses on immunology and oncology, areas that Rigel Pharmaceuticals also targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in treating cancer and other serious diseases, competing with Rigel in the biotech and pharmaceuticals industry.

About

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Show more...
CEO
Raul R. Rodriguez
Employees
174
Country
United States
ISIN
US7665597024
WKN
000A40EFY

Listings

F
DE
RI2.F
STU
DE
RI2.STU
MU
DE
RI2A.MU
MU
DE
RI2.MU

0 Comments

Share your thoughts

FAQ

What is Rigel Pharmaceuticals stock price today?▼
The current price of RIGL is $43.62 USD — it has increased by +2.76% in the past 24 hours. Watch Rigel Pharmaceuticals stock price performance more closely on the chart.
What is Rigel Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Rigel Pharmaceuticals stocks are traded under the ticker RIGL.
Is Rigel Pharmaceuticals stock price growing?▼
RIGL stock has risen by +4.18% compared to the previous week, the month change is a +7.6% rise, over the last year Rigel Pharmaceuticals has showed a +12.02% increase.
What is Rigel Pharmaceuticals market cap?▼
Today Rigel Pharmaceuticals has the market capitalization of 814.82M
When is the next Rigel Pharmaceuticals earnings date?▼
Rigel Pharmaceuticals is going to release the next earnings report on November 10, 2026.
What were Rigel Pharmaceuticals earnings last quarter?▼
RIGL earnings for the last quarter are 0.88 USD per share, whereas the estimation was 0.09 USD resulting in a +903.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rigel Pharmaceuticals revenue for the last year?▼
Rigel Pharmaceuticals revenue for the last year amounts to 294.28M USD.
What is Rigel Pharmaceuticals net income for the last year?▼
RIGL net income for the last year is 367.02M USD.
How many employees does Rigel Pharmaceuticals have?▼
As of August 19, 2026, the company has 174 employees.
In which sector is Rigel Pharmaceuticals located?▼
Rigel Pharmaceuticals operates in the Health & Wellness sector.
When did Rigel Pharmaceuticals complete a stock split?▼
The last stock split for Rigel Pharmaceuticals was on June 27, 2024 with a ratio of 1:10.
Where is Rigel Pharmaceuticals headquartered?▼
Rigel Pharmaceuticals is headquartered in SOUTH SAN FRANCISCO, United States.